New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTesofensine vs Tirzepatide

Tesofensine vs Tirzepatide

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
Tesofensine
GLP-1 / Weight Loss Agonists
Tirzepatide
Summary
Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
Half-Life
8-10 days (exceptionally long; accumulates over weeks)
~5 days
Admin Route
Oral
SubQ
Research
Typical Dose
0.25-0.5 mg per day
2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
Frequency
Once daily
Once weekly, subcutaneous
Key Benefits
  • Potent appetite suppression via triple monoamine reuptake inhibition
  • Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
  • Increases basal metabolic rate and energy expenditure
  • Reduces fat mass preferentially over lean mass
  • Potential cognitive benefit via dopaminergic and noradrenergic enhancement
  • Longer half-life than sibutramine allows once-daily dosing
  • Average 21% body weight reduction at highest dose (SURMOUNT-1)
  • Superior to semaglutide in head-to-head SURPASS trials
  • Dual GIP/GLP-1 mechanism for enhanced metabolic control
  • Significant reduction in HbA1c for type 2 diabetes
  • Improved cardiovascular risk markers
  • Reduces visceral fat preferentially
  • FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
  • Weekly dosing
Side Effects
  • Elevated heart rate and blood pressure (sympathomimetic)
  • Dry mouth
  • Insomnia and sleep disturbances
  • Nausea
  • +4 more
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal pain
  • +3 more
Stacks With